Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;5(2):169-72.
doi: 10.1002/emmm.201202388. Epub 2013 Jan 22.

Journeys into the genome of cancer cells

Michael R Stratton  1
Affiliations

Journeys into the genome of cancer cells

Michael R Stratton. EMBO Mol Med. 2013 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. The cellular lineage between a fertilized egg and a fully malignant cancer cell
Coloured symbols represent the accumulation of somatic mutations over a lifetime. The number of driver mutations reflects the number of biological processes that need to be subverted to convert a normal cell into a cancer cell. The genes in which driver mutations occur (cancer genes) can present tractable targets for new drug development. The number of passenger mutations reflects the number of mitoses between the fertilized egg and the cancer cell and the mutation rate at each mitosis. Passenger mutations provide insights into the underlying mutational processes operative in each case.
Figure 2
Figure 2. The genome-wide rearrangements in six breast cancer genomes (three cell lines, top and three primary tumours, below)
In each case, the genome is represented as a circle and the lines represent somatic rearrangements, green are intrachromosomal and purple interchromosomal. First published in Stephens et al (2009).
See this image and copyright information in PMC

References

    1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley B, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. - PubMed
    1. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–819. - PMC - PubMed
    1. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–575. - PMC - PubMed
    1. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153–158. - PMC - PubMed
    1. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, et al. Mutational processes moulding the genomes of 21 breast cancers. Cell. 2012;149:979–993. - PMC - PubMed

Personal name as subject